Boston Scientific

Latest Headlines

Latest Headlines

Boston Scientific earns CE mark for second-gen Watchman implant to prevent stroke

On the heels of a reimbursement setback in the U.S., Boston Scientific announced that it has received a CE mark for the second-generation Watchman FLX implant to prevent stroke by plugging the heart's left atrial appendage.

Boston Scientific recall of its cardiology guidewire deemed Class 1 by FDA

The FDA just publicized the voluntary Class 1 recall of Boston Scientific's RotaWire Elite and wireClip Torquer Guidewire and Guidewire Manipulation Device because of complaints of wire fracture.

Boston Sci's Watchman hit by restrictive CMS coverage decision, recall over blood leakage

Boston Scientific's stroke-preventing Watchman was just hit by bad news on multiple fronts. The FDA revealed that the Watchman is the subject of two Class 2 recalls, while the Centers for Medicare & Medicaid Services has just deemed reimbursement of the device "not reasonable and necessary."

Boston Sci moves deeper into oncology with $70M+ purchase from CeloNova

Cardiovascular-focused Boston Scientific is moving deeper into oncology and expanding its vascular offerings with the purchase of the interventional radiology portfolio of CeloNova BioSciences. The deal with the San Antonio, TX-based startup involves a $70 million upfront payment with additional, undisclosed regulatory and sales milestones.

Boston Scientific files patent infringement suit against Edwards' Sapien 3 TAVR

Boston Scientific is alleging that Edwards' Sapien 3 TAVR infringes its patents related to adaptive sealing technology in an intellectual-property lawsuit filed against the competitor in Germany.

Optimism about Synergy stent launch pushes Boston Sci stock up 9%, despite quarterly loss

Boston Scientific said during its Q3 earnings call that it is going to charge a premium for its Synergy drug-eluting stent in the U.S., as it seeks to capitalize on becoming the first company to earn FDA approval for a (partially) bioresorable stent.

Doctor says media exaggerated findings from recent TAVR study, and more quick hits from TCT

The ongoing Transcatheter Cardiovascular Therapeutics conference in San Francisco couldn't be any more timely, with bigwigs Abbott, Edwards, and Medtronic dropping more than $1 billion on the burgeoning transcatheter mitral valve repair/replacement market in recent months.

Boston Scientific announces $200M option to purchase Israeli transcatheter mitral valve player

Boston Scientific announced that it has obtained an exclusive $200 million option to acquire Israel's MValve Technologies, maker of a transcatheter mitral valve replacement system for mitral regurgitation. Boston Scientific also said it is providing additional financing to the company in anticipation of a first in-human clinical trial.

Boston Scientific tests the waters with a remote patient monitoring innovation challenge

Remote patient monitoring isn't a core business for Boston Scientific, but it is looking to gain access to the most cutting-edge tech in the field. It's launched the Boston Scientific Connected Patient Challenge: an open innovation challenge to solicit ideas and collaborations for remote patient monitoring.

Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access

The typical approach to achieving consistent and high-quality vascular access for chronic kidney disease patients in need of dialysis is to surgically construct an arteriovenous (AV) fistula, creating a direct connection between an artery and a vein in the arm. Startup TVA Medical has a minimally invasive, catheter-based that can achieve the same goal--only without surgery.